Lian Bio LIAN
We take great care to ensure that the data presented and summarized in this overview for LianBio is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in LIAN
Top Purchases
Top Sells
About LIAN
LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, respiratory, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor for ulcerative colitis and Crohn's disease; NX-13 for ulcerative colitis; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03, an eye solution for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.
Insider Transactions at LIAN
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|
Apr 09
2024
|
Ehong Gu Interim CFO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
17,889
-100.0%
|
$0
$0.32 P/Share
|
|
Feb 15
2024
|
Perceptive Advisors LLC Director |
SELL
Payment of exercise price or tax liability
|
Indirect |
38,436
-52.94%
|
$153,744
$4.76 P/Share
|
|
Feb 15
2024
|
Perceptive Advisors LLC Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
72,600
+50.0%
|
$145,200
$2.52 P/Share
|
|
Feb 15
2024
|
Konstantin Poukalov Director |
SELL
Payment of exercise price or tax liability
|
Direct |
19,218
-52.94%
|
$76,872
$4.76 P/Share
|
|
Feb 15
2024
|
Konstantin Poukalov Director |
BUY
Exercise of conversion of derivative security
|
Direct |
36,300
+50.0%
|
$72,600
$2.52 P/Share
|
|
Feb 15
2024
|
Adam Leo Stone Interim CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
19,218
-52.94%
|
$76,872
$4.76 P/Share
|
|
Feb 15
2024
|
Adam Leo Stone Interim CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
36,300
+50.0%
|
$72,600
$2.52 P/Share
|
|
Feb 15
2024
|
Susan Michele Silbermann Director |
SELL
Payment of exercise price or tax liability
|
Direct |
19,218
-52.94%
|
$76,872
$4.76 P/Share
|
|
Feb 15
2024
|
Susan Michele Silbermann Director |
BUY
Exercise of conversion of derivative security
|
Direct |
36,300
+50.0%
|
$72,600
$2.52 P/Share
|
|
Feb 15
2024
|
Anastasios Gianakakos Director |
SELL
Payment of exercise price or tax liability
|
Direct |
19,218
-26.38%
|
$76,872
$4.76 P/Share
|
|
Feb 15
2024
|
Anastasios Gianakakos Director |
BUY
Exercise of conversion of derivative security
|
Direct |
36,300
+33.26%
|
$72,600
$2.52 P/Share
|
|
Jan 02
2024
|
Ehong Gu Interim CFO |
SELL
Open market or private sale
|
Direct |
1,731
-2.21%
|
$6,924
$4.34 P/Share
|
|
Mar 29
2023
|
Jiang Qian SVP, China General Manager |
BUY
Grant, award, or other acquisition
|
Direct |
224,005
+43.47%
|
-
|
|
Mar 29
2023
|
Brianne Jahn Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
224,005
+50.0%
|
-
|
|
Mar 29
2023
|
Yi Larson Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
325,901
+50.0%
|
-
|
|
Mar 29
2023
|
Yizhe Wang Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
907,498
+50.0%
|
-
|
|
Jan 03
2023
|
Jiang Qian SVP, China General Manager |
SELL
Open market or private sale
|
Direct |
2,239
-3.22%
|
$2,239
$1.65 P/Share
|
|
Aug 18
2022
|
Perceptive Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
998,240
+21.12%
|
$1,996,480
$2.4 P/Share
|
|
May 26
2022
|
Perceptive Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
69,000
+2.46%
|
$207,000
$3.13 P/Share
|
|
May 25
2022
|
Perceptive Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
120,000
+4.31%
|
$240,000
$2.63 P/Share
|